Obinutuzumab for Follicular Lymphoma User Reviews
Brand names: Gazyva
- Buck
- Taken for 2 to 5 years
- May 26, 2022
"I received Obinutuzumab plus Bendamustine for Follicular Lymphoma. After 6 months of treatment, the lymphoma went into remission. Then I continued on with Obinutuzumab only for 2 years. I mostly struggled with fatigue, bloating, uti’s and bladder pain, shortness of breath, and occasional headaches. The medication was administered through my port every 8 weeks once I was on maintenance."
Reviews may be edited to correct grammar/spelling or to remove inappropriate language and content. Reviews that appear to be created by parties with a vested interest are not published. This information is not intended to endorse any particular medication. While these reviews may be helpful, they are not a substitute for the expertise, knowledge, and judgement of healthcare professionals.
Learn more about Follicular Lymphoma
Care guides
More about obinutuzumab
- Check interactions
- Compare alternatives
- Reviews (3)
- Side effects
- Dosage information
- During pregnancy
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
"I was diagnosed with stage 4 follicular lymphoma in December 2021 and received 6 months Chemotherapy of Obinutuzumab + Bendomustine. All went well except for tiredness, especially towards the end of the 6-month cycle, and a lot of "burping". Scans showed that I am now in partial remission. I have since had two treatments of maintenance therapy and am starting to feel well again. I am very grateful to all the people who have developed such lifesaving therapy."